Disclosed is a peramivir dry powder inhaler, comprising a peramivir API or its acceptable salt or hydrate, wherein a single-dose preparation has a content of 5˜30 mg; the particle size distribution D10 of the dry powder is 1.3˜2.2 μm, D50 is 3˜6 μm, and D90 is 6˜13 μm. The peramivir dry powder inhaler prepared can effectively lower the titer of the influenza A virus in mouse lungs, has a notable anti-virus effect, can significantly prolong survival time and reduce mortality rate. The drug efficacy of the peramivir dry powder inhaler is superior to those of the peramivir sodium chloride injection and oseltamivir phosphate. The peramivir dry powder inhaler has a specific lung targeting effect, with notable improvement in drug effectiveness and safety.

A dry powder inhaler for delivering medicament from at least one medicament carrier having a plurality of spaced-apart medicament doses. The inhaler includes a housing having regions for accommodating unused and used portions of the medicament carrier, a mouthpiece component extending from the housing and through which a user is able to inhale, a dispensing mechanism arranged in the housing for moving a medicament dose of the medicament carrier to the dispensing position, and a mouthpiece cover being rotatably connected to the housing for sequential movement about a rotation axis from a first position in which the mouthpiece component is completely covered to a second position in which the mouthpiece component is completely covered, and from the second position to a third position in which the mouthpiece component is completely uncovered, the second position being between the first and third positions.

A dry powder inhaler for delivering medicament from at least one medicament carrier having a plurality of spaced-apart medicament doses. The inhaler includes a housing having regions for accommodating unused and used portions of the medicament carrier, a mouthpiece component extending from the housing and through which a user is able to inhale, a dispensing mechanism arranged in the housing for moving a medicament dose of the medicament carrier to the dispensing position, and a mouthpiece cover being rotatably connected to the housing for sequential movement about a rotation axis from a first position in which the mouthpiece component is completely covered to a second position in which the mouthpiece component is completely covered, and from the second position to a third position in which the mouthpiece component is completely uncovered, the second position being between the first and third positions.

A method of producing microparticles by spray drying comprises the steps of providing a spray-drying feedstock solution comprising water, a volatile divalent metal salt, weak acid, 5-15% dairy or vegetable protein (w/v) and 1-20% active agent (w/v). The feedstock solution is adjusted to have a pH at which the volatile divalent metal salt is substantially insoluble. The feedstock solution is then spray-dried at an elevated temperature to provide atomised droplets, whereby the volatile divalent metal salt disassociates at the elevated temperature to release divalent metal ions which crosslink and aggregate the protein in the atomised droplets to produce microparticles having a crosslinked aggregated protein matrix and active agent dispersed throughout the matrix.

A device for dispensing a fluid product, having a body (1) and a dispensing head (2) with a dispensing orifice (3) and axially movable. The body receives a vessel (10) containing one or two doses of product. The device has an electronic module (100) with a wireless communication module (101), a geographical location module (102), and a power source (103). The device has a sensor system (201, 202) for detecting and automatically signalling an attempt to use the device, the sensor system having a first sensor (201) arranged on the dispensing head (2) and a second sensor (202) on the body, the sensor system detecting handling representative of an attempt to use the device when the first and second sensors (201, 202) are activated simultaneously, the wireless communication module designed to make an automatic emergency call when the sensor system detects handling representative of an attempt to use the device.

A system may include an external device and an inhaler. The external device may include a processor, a communication circuit, and memory. The inhaler may include a mouthpiece, medicament, a mechanical dose counter, and an electronics module comprising a processor and a communication circuit. The electronics module may record a dosing event when the inhaler is actuated, such as when the mouthpiece cover is opened, and send a signal indicating the dosing event to the external device. The external device may receive a mechanical dose reading of the mechanical dose counter, determine an electronic dose reading based on the signal indicating the dosing event, determine that a discrepancy between the mechanical dose reading and the electronic dose reading exceeds a threshold, and notify the user of the discrepancy, for example, by providing a notification to the user by way of a mobile application residing on the external device.

A method of delivering a substance, such as one or more of a triptan, a nasal steroid or carbon dioxide gas, to the nasal cavity of a subject, in particular for the treatment of headaches, for example, migraine, or rhinosinusitis, for example, chronic rhinosinusitis, optionally with polyps, the method comprising the steps of fitting a nosepiece to one nostril of the subject, delivering the substance through the nosepiece to the posterior region of the nasal cavity of the subject.

An inhaler for facilitating inhalation of dry powder includes a body defining an interior space and a mouth piece. At least one annular member is positioned within the interior space and is rotatable with respect to the mouth piece. The at least one annular member includes a plurality of compartments. Each compartment defines a cavity configured to hold dry powder. Each compartment includes at least one flap and an opening configured to release the dry powder when the at least one flap is reconfigured from a closed position to an open position. The at least one flap covers the opening and inhibits the dry powder from being released from the cavity in the closed position.

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.